Orion Biotech Opportunities Corp.

Underwriter: Cantor Fitzgerald
SPAC Ticker
Biotech, Life Sciences
External link: SEC Filings



James Huang is Orion’s Chief Executive Officer and serves on Orion’s board of directors. Mr. Huang is the Founding Managing Partner of Panacea and has over 30 years of experience in the healthcare sector as a successful entrepreneur, investor, and an opinion leader. Mr. Huang is also a managing partner of Kleiner Perkins Caufield & Byers China. He has co-founded and/or financed several innovative life sciences companies, including GenScript (HK:1548), Sutro Biopharma (NASDAQ: STRO), Legend Biotech (NASDAQ: LEGN), Zai Lab (NASDAQ: ZLAB), and Zhaoke Ophthalmology (IPO filed in HKSE).

Mr. Huang joined Kleiner Perkins Caufield & Byers China in 2011 and focuses on the firm’s life sciences practice. Prior to this, Mr. Huang was a Managing Partner at Vivo Ventures, a Venture Capital firm specializing in life sciences investments. Before joining Vivo Ventures in 2007, Mr. Huang was president of Anesiva, a biopharmaceutical company focused on pain-management treatments. During his 20-year career in the pharmaceutical and biotechnology industry, he also held senior roles in business development, sales, marketing and R&D with Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp. (acquired by Johnson & Johnson). Mr. Huang is Chairman of the Board at Eden Biologics, TriArm Therapeutics, XW Pharma, Ziopharm Oncology (NASDAQ: ZIOP), Windtree Therapeutics (NASDAQ: WINT) and serves as a director on the boards of OncXerna, CASI Pharma (NASDAQ: CASI), Tactiva Therapeutics and Kindstar Global. Mr. Huang invested in GenScript (HK: 1548), including its subsidiary Legend Biotech (NASDAQ: LEGN), when it was a small U.S. venture backed company, participating in its growth into a revenue-generating company with a multi-billion dollar valuation and public listings on the Hong Kong Stock Exchange and Nasdaq. Mr. Huang received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in chemical engineering from the University of California, Berkeley.

Chrystyna Bedrij Stecyk is a Vice President of Orion. Ms. Bedrij Stecyk is a Co-Founder and Principal of Griffin Securities, an equity research and investment banking firm specializing in biotechnology, technology, and energy. She has over 20 years of experience in biotechnology as a research analyst, investment banker, business development professional, and incubator of new biotechnology companies. Her experience spans multiple therapeutic areas, including oncology, rare disease, and the central nervous system across a wide range of modalities.

In 2013 she incubated and co-founded Agilis Therapeutics, which was purchased by PTC Therapeutics in 2018 for approximately $1 billion in cash, stock, and milestones, excluding royalties. She is also co-founder and manager of several new private companies focused on developing state-of-the-art therapeutics. Ms. Bedrij Stecyk has served on the board of directors of Vaccinex (NASDAQ: VCNX) since May 2020 and is a member of the audit committee. She has a Master of Business Administration in Finance from New York University’s Leonard N. Stern of Business and a Bachelor of Arts in Economics from Vassar College.

Mark Kayal is Orion’s Chief Financial Officer and Secretary. Mr. Kayal is the Senior Controller of MSD Partners. Prior to joining MSD Partners in 2011, Mr. Kayal was a Senior Auditor at PricewaterhouseCoopers LLP in the Banking and Capital Markets Practice. Mr. Kayal is the Head of Valuation and oversees the MSD Partners accounting and valuation teams. Mr. Kayal holds a Bachelor of Science in Accounting & Philosophy from the University of Scranton. Mr. Kayal is a Certified Public Accountant in the State of New York and is a member of the American Institute of Certified Public Accountants.

Samuel Broder, M.D. has agreed to serve on our board of directors. Prior to his retirement, Dr. Broder was Senior Vice President from 2012 to June 2016 and Head of the Health Sector from 2015 to June 2016 for Intrexon Corporation, a synthetic biology company. Prior to Intrexon, he served as the Executive Vice President for Medical Affairs and Chief Medical Officer at Celera Corporation from 1998 to 2010. Prior to Celera, Dr. Broder served as Senior Vice President, Research and Development and Chief Scientific Officer at IVAX Corporation from 1995 to 1998.

Dr. Broder served as the director of the National Cancer Institute from 1989 to 1995 appointed by President Ronald Reagan, where he oversaw the development of numerous anti-cancer therapeutic agents. Dr. Broder has served as a member of the board of directors of Sensei Biotherapeutics since April 2019.

Dr. Broder received a B.S. from University of Michigan and an M.D. from the University of Michigan Medical School, with post-graduate training at Stanford University in Palo Alto.

James Collins, Ph.D. , has agreed to serve on Orion’s board of Directors. Dr. Collins is the Termeer Professor of Medical Engineering & Science and Professor of Biological Engineering at the Massachusetts Institute of Technology (MIT), as well as a Member of the Harvard-MIT Health Sciences & Technology Faculty. He is also a Core Founding Faculty member of the Wyss Institute for Biologically Inspired Engineering at Harvard University, and an Institute Member of the Broad Institute of MIT and Harvard. He is one of the founders of the field of synthetic biology, and his research group is focused on using synthetic biology to create next-generation diagnostics and therapeutics.

Dr. Collins has co-founded several biotechnology and life sciences companies, including Synlogic (NASDAQ: SYBX), Cellarity, Senti Biosciences, and Sherlock Biosciences. He serves on the Board of Directors of Cellarity, Sherlock Biosciences, and Fulcrum Therapeutics (NASDAQ: FULC). Dr. Collins also serves on the Scientific Advisory Board of multiple biotechnology and life sciences companies, including Synlogic, Senti Biosciences, Shape Therapeutics, and Danaher Corporation (NYSE: DHR).

Dr. Collins has received numerous awards for his research in biotechnology, including a MacArthur “Genius” Award, the Dickson Prize in Medicine, and a NIH Director’s Pioneer Award. He is an elected member of all three national academies — the National Academy of Sciences, the National Academy of Engineering, and the National Academy of Medicine — in addition to the American Academy of Arts & Science and the National Academy of Inventors.

Dr. Collins received a B.A. in physics from the College of the Holy Cross and a doctorate in medical engineering from the University of Oxford, where he was a Rhodes scholar.

Robert Simonds is the General Counsel, Assistant Secretary, Vice President and a member of our board of directors. Mr. Simonds is the General Counsel and Chief Compliance Officer of MSD Partners. He joined MSD Partners in February 2015. Immediately prior to MSD Partners, he was the General Counsel and Chief Compliance Officer of Saba Capital Management. Prior to Saba, Mr. Simonds worked as the General Counsel, Chief Compliance Officer and COO of Talpion Fund Management, L.P., as well as the Chief Compliance Officer, Head of Litigation and Corporate Counsel at Silver Point Capital. He began his legal career as a litigation associate at Cravath, Swaine & Moore, which he joined in 2003 after completing a federal clerkship on the U.S. Court of Appeals for the Third Circuit.

Mr. Simonds received a B.A. from Hamilton College, an Ed.M from Harvard University Graduate School of Education and a J.D. from Columbia Law School.